Skip to content

Technology

Powered by EIS and AI – A new standard in skin diagnostics
At the heart of Nevisense is a patented combination of Electrical Impedance Spectroscopy (EIS) and artificial intelligence. Together, they deliver high-resolution insights into the structure and integrity of skin tissue – far beyond what the eye can see.

Electrical Impedance Spectroscopy (EIS)

EIS measures how skin tissue responds to low electrical currents at different frequencies. Each frequency penetrates to different depths, allowing for a layered analysis of skin composition. This technique captures changes in cellular architecture, density and orientation – markers that may indicate disease or barrier dysfunction.
1351

Established technology

  • 300,000 + patients evaluated to date.

     

  • 500+ clinics using Nevisense for skin cancer detection.

     

  • 39 scientific publications in skin cancer, including 5,000 patients.

Nevisense Clinical guidelines established by the German Skin Cancer Society of Dermatologists (Onkoderm). Supported by US top Clinicians in a recently published Consensus Report. FDA Approved, CE Mark in Europe, TGA Approved in Australia. 

cell-changes

AI-driven diagnostic interpretation

Raw impedance data are processed by proprietary machine learning algorithms, generating a Nevisense score that supports clinical or research decision-making. The algorithms are trained on extensive datasets and continuously updated based on new findings.

5G5A9708

Non-invasive, real-time results

Nevisense measurements are quick, safe and painless. Results appear in real-time on the device display or in the cloud dashboard, supporting point-of-care or remote workflows.

Scalable and adaptable platform

The core technology supports multiple use cases – from skin cancer detection to barrier assessment and cosmetic testing. As scientific understanding and clinical needs evolve, the Nevisense platform evolves with them.